Loading news...
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
Compound Planning Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 990 shares of the biopharmaceutical company's stock, valued at approximately $557,000. Other large investors have also added to or reduced their stakes
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion.
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Fox Run Management L.L.C. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,413 shares of the biopharmaceutical company's stock, valued at approximately $2,481,000. Regeneron Pharmaceuticals comprises about
Regeneron's main growth driver should perform well through the end of the decade. The biotech should launch newer medicines in the coming years.
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placebo L'AFRS est une maladie inflammatoire chronique de type 2 des sinus caractérisée par une hypersensibilité allergique aux champignons qui nécessite souvent une intervention chirurgicale avec des taux élevés de récidive postopératoire Dupixent est maintenant approuvé aux États-Unis pour traiter neuf maladies chroniques, dues notamment à une inflammation de type 2 Dupixent est désormais approuvé aux États-Unis pour le traitement de neuf maladies distinctes liées en partie à l'inflammation de type 2, notamment des maladies sino-nasales, cutanées, gastro-intestinales et respiratoires touchant un large éventail de patients, du nourrisson à la personne âgée Paris et Tarrytown, NY, le 24 février 2026.
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults Paris and Tarrytown, NY, February 24, 2026. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 1,638 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the
Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 3.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,325 shares of the biopharmaceutical company's stock after purchasing an additional 1,365 shares during the
Citigroup Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,191 shares of the biopharmaceutical company's stock after selling 46,055 shares during the
This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development.
China Universal Asset Management Co. Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 13.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,359 shares of the biopharmaceutical company's stock after selling 3,178 shares during the quarter.
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
CenterBook Partners LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 10.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,223 shares of the biopharmaceutical company's stock after acquiring an additional 5,632 shares during the
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial.